These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36796478)

  • 1. Methods to Adjust Willingness-to-Pay Measures for Severity of Illness.
    Phelps CE; Lakdawalla DN
    Value Health; 2023 Jul; 26(7):1003-1010. PubMed ID: 36796478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).
    Lakdawalla DN; Phelps CE
    Eur J Health Econ; 2022 Apr; 23(3):433-451. PubMed ID: 34495445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.
    Stolk EA; van Donselaar G; Brouwer WB; Busschbach JJ
    Pharmacoeconomics; 2004; 22(17):1097-107. PubMed ID: 15612829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.
    Reckers-Droog V; van Exel J; Brouwer W
    Value Health; 2021 Aug; 24(8):1182-1192. PubMed ID: 34372984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concerns for the worse off: fair innings versus severity.
    Nord E
    Soc Sci Med; 2005 Jan; 60(2):257-63. PubMed ID: 15522483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework?
    Pandya A; Soeteman DI; Gupta A; Kamel H; Mushlin AI; Rosenthal MB
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006492. PubMed ID: 32615799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.
    Lakdawalla DN; Phelps CE
    Value Health; 2021 Feb; 24(2):244-249. PubMed ID: 33518031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity-Adjusted Probability of Being Cost Effective.
    Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
    Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT.
    King AJ; Fernie G; Hudson J; Kernohan A; Azuara-Blanco A; Burr J; Homer T; Shabaninejad H; Sparrow JM; Garway-Heath D; Barton K; Norrie J; McDonald A; Vale L; MacLennan G
    Health Technol Assess; 2021 Nov; 25(72):1-158. PubMed ID: 34854808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment with risk aversion in health.
    Lakdawalla DN; Phelps CE
    J Health Econ; 2020 Jul; 72():102346. PubMed ID: 32592923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.
    van de Wetering L; van Exel J; Bobinac A; Brouwer WB
    Pharmacoeconomics; 2015 Dec; 33(12):1289-300. PubMed ID: 26232199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
    Nord E
    Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the use of the proportional shortfall help align the prioritisation of health services with public preferences?
    Richardson J; Iezzi A; Maxwell A; Chen G
    Eur J Health Econ; 2018 Jul; 19(6):797-806. PubMed ID: 28801762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
    Franic DM; Bothe AK; Bramlett RE
    J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY.
    Nord E; Johansen R
    Health Policy; 2014 Jun; 116(2-3):281-8. PubMed ID: 24690334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable Devices for Single-Sided Deafness and Conductive or Mixed Hearing Loss: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(1):1-165. PubMed ID: 32194878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing vaccines using value of statistical life measures.
    Laxminarayan R; Jamison DT; Krupnick AJ; Norheim OF
    Vaccine; 2014 Sep; 32(39):5065-70. PubMed ID: 25045822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial.
    Brittenden J; Cotton SC; Elders A; Tassie E; Scotland G; Ramsay CR; Norrie J; Burr J; Francis J; Wileman S; Campbell B; Bachoo P; Chetter I; Gough M; Earnshaw J; Lees T; Scott J; Baker SA; MacLennan G; Prior M; Bolsover D; Campbell MK
    Health Technol Assess; 2015 Apr; 19(27):1-342. PubMed ID: 25858333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.